Equities

Vericel Corp

Vericel Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)23.64
  • Today's Change-0.63 / -2.60%
  • Shares traded161.94k
  • 1 Year change-54.70%
  • Beta2.0012
Data delayed at least 15 minutes, as of Oct 07 2022 20:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • VCEL:NAQ price moved over +1.42% to 23.53
  • VCEL:NAQ trading volume exceeds daily average by +21.06%
  • VCEL:NAQ price falls below 15-day moving average to 23.78 at 10:30 BST
  • VCEL:NAQ price rises above 15-day moving average to 24.37 at 12:31 BST

Key statistics

As of last trade Vericel Corp (VCEL:NAQ) traded at 23.64, 7.16% above its 52-week low of 22.06, set on Sep 06, 2022.
52-week range
Today
22.06Sep 06 202252.87Oct 08 2021
Markit short selling activity
Low
Med
High
Open23.78
High24.04
Low23.45
Bid23.64
Offer23.69
Previous close24.27
Average volume494.41k
Shares outstanding47.18m
Free float46.84m
P/E (TTM)--
Market cap1.09bn USD
EPS (TTM)-0.35
USD
Data delayed at least 15 minutes, as of Oct 07 2022 20:10 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.